Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 57,225 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 57,225 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $0.87, for a total transaction of $49,785.75. Following the completion of the transaction, the insider owned 4,867,341 shares of the company’s stock, valued at $4,234,586.67. This trade represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Thursday, December 4th, Ansbert Gadicke sold 83,230 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $80,733.10.
• On Tuesday, December 2nd, Ansbert Gadicke sold 59,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $52,756.53.
• On Monday, December 1st, Ansbert Gadicke sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $57,261.98.
• On Friday, November 28th, Ansbert Gadicke sold 20,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $20,074.23.
• On Wednesday, November 26th, Ansbert Gadicke sold 60,733 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $59,518.34.
• On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.92, for a total value of $39,130.36.
• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $87,025.96.
• On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $62,344.56.

Werewolf Therapeutics Stock Up 8.5%

Shares of NASDAQ HOWL traded up $0.08 during trading on Thursday, reaching $1.00. The company had a trading volume of 587,802 shares, compared to its average volume of 504,491. The stock has a market cap of $48.36 million, a PE ratio of -0.61 and a beta of 0.74. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.38. The business’s 50-day moving average is $1.42 and its 200 day moving average is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOWL has been the subject of several research analyst reports. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. JMP Securities cut their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Finally, Bank of America dropped their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

Institutional Trading of Werewolf Therapeutics

Large investors have recently made changes to their positions in the business. Susquehanna International Group LLP grew its position in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares during the period. Citadel Advisors LLC purchased a new position in Werewolf Therapeutics during the third quarter valued at approximately $304,000. Vanguard Group Inc. raised its position in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Bridgeway Capital Management LLC lifted its holdings in Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after acquiring an additional 62,414 shares during the period. Finally, Bank of America Corp DE boosted its position in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.